Reticulospinal Control of Movements

Sponsor
University of Zurich (Other)
Overall Status
Recruiting
CT.gov ID
NCT04967274
Collaborator
(none)
102
1
1
32.5
3.1

Study Details

Study Description

Brief Summary

Accurate movement execution is a result of a complex interplay between various muscle groups whose activity is controlled by different areas of the central nervous system. Besides the corticospinal system, the phylogenetically old reticulospinal system is a key motor system controlling different elementary movements including posture, locomotion and reaching across all mammals. In contrast to the extensively investigated corticospinal system, there is only sparse knowledge on the motor physiology of the functionally important reticulospinal system in humans. Reticulospinal motor control can be assessed with the StartReact paradigm which is based on the activation of reticulospinal motor circuitries by startling acoustic stimuli. The StartReact phenomenon is characterized by a shortening in movement reaction time which is mediated by a startle-triggered, early release of a planned motor program by the reticulospinal system. Thus, StartReact is a unique tool to examine reticulospinal involvement on human motor control under physiological and pathological conditions. StartReact assessments will be supplemented by comprehensive 3-D kinematic analysis and muscle activity recordings (i.e. electromyography) to gain quantitative insights into reticulospinal movement control.

The first objective of this clinical study is to gain more insights into the mechanisms underlying StartReact and to advance the knowledge on reticulo-spinal motor physiology regarding different movement tasks (i.e. simple single-joint movements, complex multi-joint movements and bilateral hand movements) in healthy subjects. The findings of these experiments will provide new insights into proximal-distal, flexor-extensor and upper-lower extremity gradients in reticulospinal motor control of healthy subjects. Moreover, the results will expand the StartReact paradigm to complex, functionally more relevant movements (i.e. reaching and stepping tasks requiring endpoint accuracy; co-operative, bilateral hand movements) for which the involvement of the reticulo-spinal system is not yet understood.

The second goal of this project is to use the StartReact paradigm to shed more light onto the role of reticulospinal plasticity in functional recovery of patients with spinal cord injury (SCI). Whereas preclinical findings emphasize a remarkable potential of the reticulospinal system for neuroplastic adaptations underlying functional recovery, there is only little evidence from clinical trials in the field of SCI. First, the study aims at monitoring StartReact effects in hand and leg muscles of patients with acute SCI over a period of 6 months. Simultaneous tracking of StartReact effects and motor recovery will allow to closely relate processes of reticulospinal plasticity to functional recovery in patients with acute SCI. Second, the focus will be on the re-weighting of descending motor control (i.e. cortico- vs. reticulospinal system) in response to SCI and investigate the distinct contributions of the cortico- and reticulospinal system to motor recovery in patients with chronic SCI.

The findings of this project will advance the mechanistic understanding on the motor physiology and neurorestorative capacity of the reticulospinal system in humans. New insights from these projects will hopefully translate into a better exploitation of this important motor system in clinical trials that aim to improve motor recovery in patients with SCI.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Startling acoustic stimulus
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
102 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Each participants receives real and control interventions.Each participants receives real and control interventions.
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Contributions of the Reticulospinal System to Movement Control and Functional Recovery in Patients With Spinal Cord Injury
Actual Study Start Date :
Jan 15, 2022
Anticipated Primary Completion Date :
Sep 30, 2024
Anticipated Study Completion Date :
Sep 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Spinal cord injured subjects

Procedure: Startling acoustic stimulus
StartReact: involuntary triggering of a planed movement by a loud acoustic stimulus.

Outcome Measures

Primary Outcome Measures

  1. EMG analysis (i.e. shortening of movement reaction time of target muscle(s)) during Loud vs. Moderate Acoustic Stimuli (LAS vs. MAS) [Baseline]

  2. Change in EMG analysis (i.e. shortening of movement reaction time of target muscle(s)) [Change in shortening of movement reaction time between baseline and visit 1 (7-14 days).]

  3. Change in EMG analysis (i.e. shortening of movement reaction time of target muscle(s)) [Change in shortening of movement reaction time at 3 and 6 months relative to baseline.]

  4. Intramuscular coherence of paired EMG signals of the tibialis anterior muscle to assess corticospinal drive in the StartReact paradigm. [Baseline]

  5. Modulation of EMG reflex responses (as induced by electrical ulnar nerve stimulation) by simultaneous acoustic stimulation with LAS [Baseline]

  6. Transcranial magnetic stimulation (TMS) to investigate corticospinal physiology/ integrity. [Baseline]

Secondary Outcome Measures

  1. Analysis of movement patterns of fast vs. slow movements based on 3D kinematics. [Baseline]

  2. Endpoint accuracy of fast vs. slow reaching and stepping movements based on a combined Virtual Reality (VR)/ kinematic system. [Baseline]

  3. Graded Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP) to measure upper extremity function (only for SCI) [The outcome is used for 2 sub-projects of this study: one sub-project conducts GRASSP at > 12 months after spinal cord injury, whereas the other sub-project conducts GRASSP at 3 visits (at < 1, 3 and 6 months after spinal cord injury).]

  4. International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) (only for SCI) [The outcome is used for 2 sub-projects of this study: one sub-project conducts ISNCSCI at > 12 months after spinal cord injury, whereas the other sub-project conducts ISNCSCI at 3 visits (at < 1, 3 and 6 months after spinal cord injury).]

  5. 10-meter walk test (only for SCI) [Baseline]

  6. 6-minute walk test (only for SCI) [Baseline]

  7. Modified Ashworth Scale (MAS) (only for SCI) [Baseline]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Written informed consent as documented by signature
For SCI patients:
  • ASIA Impairment scale (AIS) A-D

  • Focal damage at cervical (C4-C7; i.e. damage rostral of the spi-nal segments innervating the examined hand and leg muscles) or thoracic (T4-T12; i.e. damage caudal of the spinal segments innervating the m. abductor digiti minimi, but rostral of the spi-nal segments innervating the m. tibialis anterior)

  • Patients with cervical SCI must reveal bilaterally intact ulnar nerves as demonstrated by normal compound motor action potential (cMAP), nerve conduction velocity (NCV) and F-wave latencies in clinical neurography.

  • Patients with thoracic SCI must reveal bilaterally intact tibial and peroneal nerves as demonstrated by normal cMAP, NCV and F-wave latencies

Exclusion Criteria:
  • Women who are pregnant or breast feeding

  • Current neurological problems other than SCI and related impairments

  • Current orthopaedic problems affecting upper and lower extremity movements

  • History of alcohol abuse or the intake of psychotropic drugs

  • History of major cardiac condition (e.g., infarction, insufficiency (NYHA II-IV))

  • History of major pulmonary condition (e.g., chronic obstructive pulmonary disease (GOLD II-IV))

  • Current major depression or psychosis

  • Fever of unknown origin

Contacts and Locations

Locations

Site City State Country Postal Code
1 Balgrist University Hospital Zürich Switzerland 8008

Sponsors and Collaborators

  • University of Zurich

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Zurich
ClinicalTrials.gov Identifier:
NCT04967274
Other Study ID Numbers:
  • 2021-00973
First Posted:
Jul 19, 2021
Last Update Posted:
Aug 16, 2022
Last Verified:
Aug 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2022